What is it?
What brivaracetam is
1Brivaracetam is a prescription antiseizure medicine. In the United States, the BRIVIACT label covers partial-onset seizures in patients aged 1 month and older; it is not a dietary supplement or a general cognitive enhancer.
Names, aliases and forms
Mechanisms of action
SV2A-targeted antiseizure activity
2Brivaracetam binds synaptic vesicle protein 2A (SV2A), a protein involved in neurotransmitter release. This mechanism supports its antiseizure medicine role; it does not establish a nootropic benefit.
Potential effects and evidence map
Brivaracetam has regulatory-reviewed clinical evidence for its labelled seizure indication. That evidence does not establish benefit for focus, memory, or other nootropic uses in people without the labelled condition.
Regulatory-reviewed evidence does not establish brivaracetam as a focus or attention enhancer in people without the labelled seizure condition.
Typical dosages and timing
The U.S. label describes a 25 to 100 mg twice-daily range for adults. The prescriber selects the regimen based on the individual and co-medications; this is labelled context, not a personal instruction.
Timing & effect horizon
For tablets without food, the DailyMed label reports a median peak time of about 1 hour and an elimination The time for blood levels to fall by half during the final elimination phase.Source of about 9 hours. These figures do not predict seizure control onset or personal response.
Safety, side effects and risk profile
Somnolence, fatigue, dizziness, and coordination difficulties can impair driving or other hazardous activities.
Dizziness is among the common adverse reactions described in regulatory product information.
Some medicines and alcohol can affect brivaracetam exposure or impairment; medication review belongs with the prescriber or pharmacist.
Regulatory information describes somnolence, fatigue, dizziness, and coordination difficulties. Antiseizure medicines also carry warnings about suicidal thoughts or behaviour; new or worsening mood or behavioural symptoms need prompt clinical attention.
Interactions and cautions
The U.S. label includes dose considerations with CYP2C19 inhibitors and notes increased psychomotor impairment with alcohol. The full medicine and substance list should be reviewed by the prescriber or pharmacist rather than managed from a comparison page.
Legal and regulatory status
As of 2026, United States BRIVIACT prescribing information identifies brivaracetam as a Schedule V controlled substance and a prescription medicine.
As of 2026, in the European Union, Briviact is authorised as a prescription epilepsy medicine. Availability and rules remain jurisdiction-specific.
Practical buying and quality notes
- No brivaracetam offers are currently mapped on NootropicsIndex. This page does not compare or recommend unverified online sellers; lawful dispensing and price depend on a valid prescription, pharmacy, and jurisdiction.1
FAQ
Is brivaracetam a nootropic?
1No established regulatory-reviewed evidence supports brivaracetam as a focus, memory, or productivity enhancer. Its labelled role is seizure management under prescription care.
Can I compare its price with supplement listings?
2No. Brivaracetam is a prescription medicine, not a supplement. Prescription access, formulation, pharmacy pricing, reimbursement, and legal status need to be considered within the applicable healthcare system.